Shares of ADMA Biologics Inc (NASDAQ:ADMA) have earned a consensus recommendation of “Buy” from the eight ratings firms that are currently covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have covered the stock in the last year is $11.58.
A number of equities analysts have commented on ADMA shares. Oppenheimer set a $13.00 price objective on shares of ADMA Biologics and gave the stock a “buy” rating in a report on Monday, August 13th. HC Wainwright set a $17.00 price objective on shares of ADMA Biologics and gave the stock a “buy” rating in a report on Friday, November 9th. Maxim Group reaffirmed a “buy” rating and issued a $12.00 price objective on shares of ADMA Biologics in a report on Wednesday, October 17th. Raymond James reaffirmed a “buy” rating and issued a $10.00 price objective (down previously from $11.00) on shares of ADMA Biologics in a report on Friday, October 12th. Finally, BidaskClub raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a report on Wednesday, September 5th.
Institutional investors and hedge funds have recently made changes to their positions in the company. 683 Capital Management LLC boosted its holdings in shares of ADMA Biologics by 9.9% during the second quarter. 683 Capital Management LLC now owns 885,000 shares of the biotechnology company’s stock valued at $3,991,000 after acquiring an additional 80,000 shares during the period. BlackRock Inc. boosted its holdings in shares of ADMA Biologics by 59.5% during the first quarter. BlackRock Inc. now owns 40,536 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 15,115 shares during the period. AMP Capital Investors Ltd acquired a new position in shares of ADMA Biologics during the second quarter valued at $109,000. Renaissance Technologies LLC acquired a new position in shares of ADMA Biologics during the second quarter valued at $132,000. Finally, Ardsley Advisory Partners acquired a new position in shares of ADMA Biologics during the second quarter valued at $361,000. 57.72% of the stock is owned by institutional investors.
ADMA Biologics stock traded down $0.19 during mid-day trading on Friday, reaching $4.74. The company’s stock had a trading volume of 96,956 shares, compared to its average volume of 109,645. The company has a market cap of $219.70 million, a PE ratio of -2.48 and a beta of 2.27. The company has a debt-to-equity ratio of 1.11, a current ratio of 6.32 and a quick ratio of 4.92. ADMA Biologics has a twelve month low of $2.42 and a twelve month high of $6.96.
ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.02). The business had revenue of $4.23 million during the quarter, compared to analyst estimates of $5.39 million. ADMA Biologics had a negative return on equity of 155.19% and a negative net margin of 243.42%. Equities research analysts anticipate that ADMA Biologics will post -1.37 earnings per share for the current year.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Further Reading: What is the Consumer Price Index (CPI)?
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.